VEGFA and hepatocellular carcinoma: Our results could support the basis of concept that lenvatinib, a first line drug for HCC, synergizes with immunotherapy to inhibit the immunosuppressive tumor environment, via the inhibition of the monocytes to tumor-associated macrophages transition or the inhibition of vascular endothelial growth factors as the main mechanism [32,33].